Anti-Filamin A (phospho S1458) antibody [EP2309Y] (ab68424)

Overview

  • Product nameAnti-Filamin A (phospho S1458) antibody [EP2309Y]
    See all Filamin A primary antibodies
  • Description
    Rabbit monoclonal [EP2309Y] to Filamin A (phospho S1458)
  • SpecificityDetects Filamin A only when phosphorylated at serine 1458.
  • Tested applicationsSuitable for: WB, IHC-P, ICC/IFmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic phosphopeptide corresponding to residues surrounding serine 1458 of Human Filamin A

  • Positive control
    • HeLa cells. Stomach. Uterus.
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Applications

Our Abpromise guarantee covers the use of ab68424 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Detects a band of approximately 260 kDa (predicted molecular weight: 280 kDa).
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC/IF 1/50 - 1/100.
  • Application notesIs unsuitable for Flow Cyt or IP.
  • Target

    • FunctionPromotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.
    • Tissue specificityUbiquitous.
    • Involvement in diseaseDefects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period.
      Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood.
      Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum.
      Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects.
      Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies.
      Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull.
      Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion.
      Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation.
      Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females.
      Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets.
    • Sequence similaritiesBelongs to the filamin family.
      Contains 1 actin-binding domain.
      Contains 2 CH (calponin-homology) domains.
      Contains 24 filamin repeats.
    • DomainComprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.
    • Post-translational
      modifications
      Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation.
      The N-terminus is blocked.
    • Cellular localizationCytoplasm > cell cortex. Cytoplasm > cytoskeleton.
    • Information by UniProt
    • Database links
    • Alternative names
      • ABP 280 antibody
      • ABP-280 antibody
      • Actin-binding protein 280 antibody
      • Alpha filamin antibody
      • Alpha-filamin antibody
      • APBX antibody
      • CSBS antibody
      • CVD1 antibody
      • Endothelial actin binding protein antibody
      • Endothelial actin-binding protein antibody
      • Filamin 1 antibody
      • Filamin A alpha antibody
      • Filamin A antibody
      • Filamin-1 antibody
      • Filamin-A antibody
      • FLN antibody
      • FLN-A antibody
      • FLN1 antibody
      • FLNA antibody
      • FLNA_HUMAN antibody
      • FMD antibody
      • MNS antibody
      • NHBP antibody
      • Non muscle filamin antibody
      • Non-muscle filamin antibody
      • OPD antibody
      • OPD1 antibody
      • OPD2 antibody
      • XLVD antibody
      • XMVD antibody
      see all

    Anti-Filamin A (phospho S1458) antibody [EP2309Y] images

    • All lanes : Anti-Filamin A (phospho S1458) antibody [EP2309Y] (ab68424) at 1/5000 dilution

      Lane 1 : HeLa cell lysate - untreated
      Lane 2 : HeLa cell lysate - treated with AP

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP-labelled Goat anti-Rabbit antibody at 1/2000 dilution

      Predicted band size : 280 kDa
      Observed band size : 260 kDa (why is the actual band size different from the predicted?)
    • Immunohistochemical analysis of paraffin-embedded human stomach (left) and human uterus tissue (right) using 1/50 ab68424. Heat-mediated antigen retrieval was performed prior to commencing with IHC protocol and an HRP-conjugated polymerized secondary antibody was used.

    References for Anti-Filamin A (phospho S1458) antibody [EP2309Y] (ab68424)

    ab68424 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab68424.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"